For the quarter ending 2025-09-30, QNCX had -$10,374K decrease in cash & cash equivalents over the period. -$10,002K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -13,442 | -31,079 |
| Stock based compensation | 1,255 | 2,659 |
| Depreciation and amortization | 36 | 67 |
| Change in the fair value of contingent consideration liabilities | 2,066 | 2,456 |
| Change in fair value of debt, net | 490 | 828 |
| Fair value adjustment for warrants | -291 | 4,464 |
| Non-cash goodwill and intangible asset impairment charge | 0 | 0 |
| Amortization of discount on available-for-sale investments | 236 | 590 |
| Prepaid expenses and other current assets | 374 | -588 |
| Right of use assets, operating leases and operating lease liabilities | -27 | -53 |
| Other assets | 486 | 121 |
| Accounts payable | 1,631 | -1,417 |
| Accrued expenses and other current liabilities | -604 | 1,076 |
| Net cash used in operating activities | -9,928 | -21,016 |
| Purchase of investments | 15,707 | 13,789 |
| Proceeds from maturities of investments | 14,000 | 31,000 |
| Purchase of property and equipment | 74 | 274 |
| Net cash provided by investing activities | -1,781 | 16,937 |
| Payment of contingent consideration | 0 | - |
| Proceeds from issuance of common stock, common warrants, and pre-funded warrants pursuant to private placement offering, net of issuance costs | 0 | 11,426 |
| Proceeds from issuance of common stock upon public offering, net of issuance costs | 1,376 | 2,890 |
| Proceeds from issuance of common stock upon exercise of stock options | 0 | 183 |
| Net cash provided by (used in) financing activities | 1,376 | 14,499 |
| Effect of exchange rate changes on cash | -41 | 194 |
| Net increase (decrease) in cash and cash equivalents | -10,374 | 10,614 |
| Cash and cash equivalents at beginning of period | 6,212 | - |
| Cash and cash equivalents at end of period | 6,452 | - |
Quince Therapeutics, Inc. (QNCX)
Quince Therapeutics, Inc. (QNCX)